Table 1.
Patient demographics, indications for KTx, graft number, compatibility data and induction agents used for the 189 patients who contributed data to the analyses presented
| Characteristic | Overall | Sample subgroups, N or mean ± SD | ||
|---|---|---|---|---|
| N | Percent or mean ± SD | Stable Phase | BPR | |
| Patients evaluated | 189 | 100% | 83 | 15 |
| Age (years) | 189 | 52 ± 14 | 49 ± 13 | 56 ± 10 |
| Gender | ||||
| Female | 69 | 36.5% | 33 | 7 |
| Male | 120 | 63.5% | 50 | 8 |
| Race | ||||
| Caucasian | 184 | 97.4% | 80 | 15 |
| Asian | 5 | 2.6% | 3 | 0 |
| Indication for KTx | ||||
| IgA nephropathy | 25 | 13.2% | 17 | 1 |
| Reflux nephropathy | 14 | 7.4% | 6 | 1 |
| FSGS | 3 | 1.6% | 1 | 0 |
| Polycystic kidney disease | 42 | 22.2% | 18 | 4 |
| Diabetes | 7 | 3.7% | 3 | 0 |
| Hypertension/nephrosclerosis | 11 | 5.8% | 4 | 2 |
| Alport syndrome | 5 | 2.6% | 1 | 0 |
| Interstitial nephropathy | 7 | 3.7% | 3 | 0 |
| Glomerulonephritis | 32 | 16.9% | 15 | 2 |
| Lupus erythematosus | 4 | 2.1% | 2 | 0 |
| Other | 38 | 20.1% | 13 | 5 |
| Prior grafts | ||||
| 0 | 161 | 85.2% | 71 | 12 |
| 1 | 23 | 12.2% | 10 | 3 |
| 2 | 4 | 2.1% | 1 | 0 |
| >2 | 1 | 0.5% | 1 | 0 |
| Donor type | ||||
| Living | 71 | 37.6% | 42 | 5 |
| Deceased | 118 | 61.9% | 41 | 10 |
| AB0 compatible | ||||
| Compatible | 165 | 87.3% | 72 | 12 |
| Incompatible | 24 | 12.7% | 11 | 3 |
| HLA mismatch | ||||
| 0 | 22 | 11.6% | 14 | 1 |
| 1‐2 | 42 | 22.2% | 23 | 1 |
| 3‐4 | 77 | 40.7% | 28 | 7 |
| 5‐6 | 48 | 25.4% | 18 | 6 |
| Induction agent | ||||
| Basiliximab | 139 | 73.5% | 59 | 10 |
| Rituximab | 21 | 11.1% | 9 | 2 |
| Thymoglobulin | 27 | 14.3% | 14 | 2 |
| Rituximab & Thymoglobulin | 2 | 1.1% | 1 | 1 |
| Delayed graft function | ||||
| Yes | 55 | 29.1% | 0 | 11 |
| No | 134 | 70.9% | 83 | 4 |
Abbreviations: BPR, biopsy‐proven rejection; FSGS, focal segmental glomerulosclerosis; HLA, human leukocyte antigen; IgA, immunoglobulin A; KTx, kidney transplant; SD, standard deviation.